Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. We co...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-01-01
|
Series: | Clinical Medicine Insights: Cardiology |
Online Access: | https://doi.org/10.4137/CMC.S4324 |